ABSTRACT
Purpose This collaborative study, led by the Clinical Genome Resource Severe Combined Immunodeficiency Disease Variant Curation Expert Panel (ClinGen SCID-VCEP), implemented and adapted the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines for interpreting germline variants in genes with established relationships to SCID. The effort focused on the 7 most common SCID-related genes identified by SCID newborn screening in North America: ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2.
Methods The SCID-VCEP conducted a rigorous review of variants that involved database analyses, literature review, and expert feedback to derive gene-specific modifications to the ACMG/AMP guidelines. These specifications were validated using a pilot set of 90 variants. Results: Of these 90 variants, 25 were classified as pathogenic, 21 as likely pathogenic, 14 as variants of uncertain significance (VUS), 18 as likely benign, and 12 as benign. Seventeen variants with conflicting classifications in ClinVar were successfully resolved. The criteria included modifications to 20 of the 28 original ACMG/AMP criteria specific to SCID-related genes.
Conclusion The SCID-specific variant curation guidelines developed by the SCID-VCEP will enhance the precision of SCID genetic diagnosis and provide a robust framework for interpreting variants in SCID-related genes, contributing to appropriate treatment of SCID.
Competing Interest Statement
VCJ: Employee and shareholder of Fulgent Genetics. MZ: No conflict of interest to declare. SM: No conflict of interest to declare. JER: No conflict of interest to declare. NK: No conflict of interest to declare. XP: No conflict of interest to declare. AN: No conflict of interest to declare. SM: Employee and shareholder of Labcorp. BM: No conflict of interest to declare. MAE: No conflict of interest to declare. MJC: Member of DSMB for Bluebird Bio, Rocket Pharma, and Chiesi Bio; royalties from UpToDate. JMP: Royalties from UpToDate. MH: Grant support from Chiesi USA. JV: No conflict of interest to declare. JW: Orca Bio, Grifols, Takeda, ADMA Biologicals, Octapharma, X4-Pharmaceuticals, Bristol-Myers Squibb. Consultant/Advisory Boards: Takeda, Pharming, Cheisi, Genpharm Speakers Bureau: Pharming, Takeda, Genpharm. Royalties from UptoDate: medical writer. Member of the DSMB (Pharming). EA: No conflict of interest to declare. AYC: Consultant to Sobi. NSCO: No conflict of interest to declare. RG: No conflict of interest to declare. MP: Employee PreventionGenetics, part of Exact Sciences. BY: No conflict of interest to declare. LDN: Royalties from UpToDate. BAJ: Employee and shareholder of GeneDx, LLC. IKC: Royalties from Wolters Kluwer for UpToDate.
Funding Statement
This publication was supported in part by the National Human Genome Research Institute of the National Institutes of Health through U24HG009650. Additionally, this work was supported by the National Institutes of Health under a grant from the National Institute of Child Health and Human Development 1U24HD104590-01. MJC's work was supported by California Institute of Regenerative Medicine CLIN2-10830 and NIH U54 AI 082973.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel submitted all variants to the ClinVar Database26 including evidence summaries detailing the data used for each classification. The detailed evidence used for the classification of these variants is available in the ClinGen Evidence Repository27. Supplemental Material 3 provides a comprehensive list of variants along with their ClinVar identifiers and the applied codes.
Additionally, it includes a curation summary for all variants.
